MorphoSys’ MOR208 Receives Breakthrough Therapy Status in US for Relapsed or Refractory DLBCL
News
The U.S. Food and Drug Administration has granted breakthrough therapy designation to MorphoSys‘ MOR208 – in combination with Revlimid (lenalidomide) – for the treatment of adult patients with relapsed or refractory diffuse ... Read more